Specify a stock or a cryptocurrency in the search bar to get a summary
Profound Medical Corp
PRNProfound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada. Address: 2400 Skymark Avenue, Mississauga, ON, Canada, L4W 5K5
Analytics
WallStreet Target Price
29.34 CADP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures PRN
Dividend Analytics PRN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PRN
Stock Valuation PRN
Financials PRN
Results | 2019 | Dynamics |